EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Trajectory timelines and treatment efficacy of 177Lu-PSMA-617 radioligand therapy for metastatic castration-resistant prostate cancer

Frédéric Pouliot, Michele Lodde, Marjorie Besançon, Vincent Castonguay, Antoine Morin-Coulombe, Vincent Fradet, Yves Fradet, Louis Lacombe, Éric Lévesque, Nicolas Marcoux, Paul Toren, Geneviève April, Frédéric Arsenault, Alexis Beaulieu, Narcisse Singbo, Céline Veilleux, Mélanie Tremblay-Boily, Vincent Tremblay, François-Alexandre Buteau, Jean-Mathieu Beauregard

Canadian Urological Association Journal · 2026-02-13 · 20 (6)

DOI: 10.5489/cuaj.9398 ↗
AbstractBibliografische Angaben

Abstract

Introduction: We aimed to evaluate the efficacy and safety of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC) following approval in the real-world Canadian clinical context. Methods: Data on the first 50 patients with mCRPC who were treated with lutetium-177-PSMA-617 at a single center in Quebec, Canada, were retrospectively analyzed. Patients were treated with 7.4 GBq of lutetium-177-PSMA-617 administered every six weeks for up to six cycles. Results: Median (95% confidence interval [CI]) patient age and pre-radioligand therapy prostate-specific antigen levels were 72.55 (65.92–76.77) years and 49.19 (15.61–180.65) ng/mL, respectively. Median (95% CI) time between oncologist referral for radioligand therapy and nuclear medicine consultation or first dose of lutetium-177-PSMA-617 were 12 (7.0–32.0) and 42 (28.0–54.0) days, respectively. Overall, 26.0% of patients completed six radioligand therapy cycles. Declines in prostate-specific antigen levels of 25%, 50%, and 90% were reached in 57%, 51%, and 17% of patients, after a median of two, two, and three cycles, respectively. At last followup, after a mean followup time of 8.5 months, 61% (25/41) of patients not on ongoing therapy were alive, with an estimated median overall survival of 13.0 months (95% CI 8.0–not reached). Conclusions: Real-world data show that use of lutetium-177-PSMA-617 in patients with mCRPC is feasible in a universal healthcare system, with comparable oncologic activity to that observed in the phase 3 VISION trial. The study is limited by the short followup and its retrospective nature.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →